<DOC>
	<DOCNO>NCT00642668</DOCNO>
	<brief_summary>This single arm study assess efficacy safety subcutaneous methoxy polyethylene glycol-epoetin beta ( Mircera ) , continuous erythropoietin receptor activator ( C.E.R.A . ) , correction and/or maintenance hemoglobin level participant chronic kidney disease renal anemia , treat erythropoiesis-stimulating agent ( ESA ) dialysis . Eligible participant receive monthly subcutaneous injection methoxy polyethylene glycol-epoetin beta initial recommend dose 1.2 micrograms/kilogram ( mcg/kg ) . The anticipated time study treatment 3-10 month , target sample size 200 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera Maintenance Treatment Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult participant , &gt; =18 year age ; Chronic renal anemia ; No ESA therapy previous 3 month . Transfusion red blood cell previous 2 month ; Poorly control hypertension require hospitalization previous 6 month ; Significant acute chronic bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>